Navigation Links
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
Date:9/25/2008

unction with the closing of this transaction.

Nuvelo was advised in the transaction by Jefferies & Company and ARCA was advised by J.P. Morgan.

Conference Call Information

Nuvelo and ARCA will hold a conference call today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss this announcement. To participate in the conference call, please dial 866-854-8095 for domestic callers and 706-634-8567 for international callers and reference conference passcode, 66253667. A telephone replay of the conference call will be available through October 2, 2008. To access the replay, please dial 800-642-1687 for domestic callers and 706-645-9291 for international callers and reference conference passcode, 66253667.

In addition, this call is being webcast Thomson/CCBN and can be accessed at Nuvelo's website at http://www.nuvelo.com or ARCA's website at http://www.arcabiopharma.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
7. China Biopharma Effects 1 for 100 Reverse Stock Split
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. Therapure Biopharma Inc. opens for business with first client contracts
10. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... TORONTO, April 3, 2012  Generex Biotechnology Corporation (OTCBB: GNBT.OB) ... (AACR) chose to spotlight a presentation on data from ... to prevent relapse in patients who have had breast ... conference.  The annual AACR meeting is one of the ...
... CAMBRIDGE, Mass., April 2, 2012   Good Start Genetics ,™ ... standard in carrier screening , today announced it completed ... Stock financing, which was led by existing investors OrbiMed ... SFE ) and SV Life Sciences . Proceeds from ...
... important step forward in developing a new material using nano-sized ... devices, with greater capacity than is currently feasible, in a ... Many modern data storage devices, like hard disk ... tiny individual magnetic sections, but their overall design is limited ...
Cached Biology Technology:Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 2Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 3Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 2Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 3Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 5Honeycombs of magnets could lead to new type of computer processing 2Honeycombs of magnets could lead to new type of computer processing 3
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
(Date:9/18/2014)... "frequent flyers" program, fruit flies surely would be eligible ... increasing numbers of fruit fly research studies. One fruit ... and another is scheduled launch to the station Sept. ... December. , Fruit flies are biomedical research models studied ... organisms can reveal the basis for health and disease ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... 11 genotypes that may increase esophageal cancer risk, according ... Cancer Prevention Research, a journal of the American ... increased risk of esophageal cancer with increasing numbers of ... the Department of Epidemiology at the University of Texas ...
... in Genome Research on Nov. 4, scientists at ... previously believed to be "junk" DNA is one of the ... 50 percent of human DNA has been referred to as ... A major source of these repeats is internal viruses that ...
... online, open-access journal PLoS ONE , led by ... children who study a musical instrument for at least ... in tests of auditory discrimination and finger dexterity (skills ... also on tests measuring verbal ability and visual pattern ...
Cached Biology News:Genetic predictors of esophageal cancer identified 2'Junk' DNA proves functional 2'Junk' DNA proves functional 3Research shows that time invested in practicing pays off for young musicians 2
... Vector NTI allows you to store and ... data in a secure central relational database. ... creates an invaluable resource for clone tracking ... easily for immediate analysis. LabShare software integrates ...
... Protein A and Protein G bind ... immunoglobulins. Protein A and Protein G conjugates ... purify immunoglobulins (antibodies) and immunoglobulin subtypes from ... and other biological fluids. These reagents are ...
... Description: ,Kit containing Dermal Fibroblasts (Mouse/BalbC) ... as a long-term culture, and is guaranteed ... continuous growth from the date supplied, when ... Dermis, mouse/BalbC, embryonic day 18.5 ,Applications: ...
... Protein A and Protein G bind specifically ... Protein A and Protein G conjugates are ... immunoglobulins (antibodies) and immunoglobulin subtypes from serum, ... other biological fluids. These reagents are also ...
Biology Products: